+

WO2003012137A3 - Methodes de detection de la maladie de parkinson - Google Patents

Methodes de detection de la maladie de parkinson Download PDF

Info

Publication number
WO2003012137A3
WO2003012137A3 PCT/FR2002/002761 FR0202761W WO03012137A3 WO 2003012137 A3 WO2003012137 A3 WO 2003012137A3 FR 0202761 W FR0202761 W FR 0202761W WO 03012137 A3 WO03012137 A3 WO 03012137A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
homozygotic
parkinson
methods
detecting
Prior art date
Application number
PCT/FR2002/002761
Other languages
English (en)
Other versions
WO2003012137A2 (fr
Inventor
Gerard Lucotte
Patrice Denefle
Marie-Francoise Rosier
Original Assignee
Aventis Pharma Sa
Gerard Lucotte
Patrice Denefle
Marie-Francoise Rosier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Gerard Lucotte, Patrice Denefle, Marie-Francoise Rosier filed Critical Aventis Pharma Sa
Priority to AU2002341044A priority Critical patent/AU2002341044A1/en
Publication of WO2003012137A2 publication Critical patent/WO2003012137A2/fr
Publication of WO2003012137A3 publication Critical patent/WO2003012137A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2517/00—Cells related to new breeds of animals
    • C12N2517/02—Cells from transgenic animals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/80—Cytochromes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/9116—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • G01N2333/91165—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5) general (2.5.1)
    • G01N2333/91171—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5) general (2.5.1) with definite EC number (2.5.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)

Abstract

Méthodes de diagnostic ou de pronostic de la maladie de Parkinson chez un sujet. Ladite méthode comprend les étapes de détection de la présence ou de l'absence de la mutation homozygote CYP2D6-B d'une part, et de la délétion homozygote de GSTM1 d'autre part. La présence conjointe de la mutation homozygote CYP2D6-B et de la délétion homozygote de GSTM1 indique que le sujet peut être atteint de la maladie de Parkinson ou bien présente un risque accru de développer la maladie de Parkinson.
PCT/FR2002/002761 2001-08-03 2002-07-31 Methodes de detection de la maladie de parkinson WO2003012137A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002341044A AU2002341044A1 (en) 2001-08-03 2002-07-31 Methods for detecting parkinson's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/10456 2001-08-03
FR0110456A FR2828212B1 (fr) 2001-08-03 2001-08-03 Methodes de diagnostic et de pronostic de la maladie de parkinson

Publications (2)

Publication Number Publication Date
WO2003012137A2 WO2003012137A2 (fr) 2003-02-13
WO2003012137A3 true WO2003012137A3 (fr) 2004-02-26

Family

ID=8866283

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/002761 WO2003012137A2 (fr) 2001-08-03 2002-07-31 Methodes de detection de la maladie de parkinson

Country Status (3)

Country Link
AU (1) AU2002341044A1 (fr)
FR (1) FR2828212B1 (fr)
WO (1) WO2003012137A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309497B2 (en) 2000-08-24 2007-12-18 Schwarz Pharma Ag Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2549158A1 (fr) * 2003-12-01 2005-06-16 Technion Research And Development Foundation Ltd. Methodes de generation de cellules souches et de corps embryonnaires comportant des mutations qui entrainent des maladies et methodes d'utilisation permettant d'etudier les troubles genetiques
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
SG10201610626PA (en) 2007-11-28 2017-01-27 Ucb Pharma Gmbh Polymorphic form of rotigotine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055853A1 (fr) * 1998-04-28 1999-11-04 Takeda Chemical Industries, Ltd. Lignee cellulaire hepatique immortalisee d'origine humaine
WO2001010902A2 (fr) * 1999-08-11 2001-02-15 Curagen Corporation Polynucleotides et polypeptides codes par ces derniers

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055853A1 (fr) * 1998-04-28 1999-11-04 Takeda Chemical Industries, Ltd. Lignee cellulaire hepatique immortalisee d'origine humaine
WO2001010902A2 (fr) * 1999-08-11 2001-02-15 Curagen Corporation Polynucleotides et polypeptides codes par ces derniers

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DALVI A ET AL: "ANTIPARKINSONIAN AGENTS CLINICALLY SIGNIFICANT DRUG INTERACTIONS AND ADVERSE EFFECTS, AND THEIR MANAGEMENT", CNS DRUGS, ADIS INTERNATIONAL, AUCKLAND, NZ, vol. 9, no. 4, April 1998 (1998-04-01), pages 291 - 310, XP000989835, ISSN: 1172-7047 *
MCCANN S ET AL: "The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis", JOURNAL OF NEUROLOGICAL SCIENCES, vol. 153, no. 1, December 1997 (1997-12-01), pages 50-53, XP001064818 *
NICHOLL D ET AL: "A study of five candidate genes in Parkinson's disease and related neurodegenerative disorders", NEUROLOGY, vol. 53, no. 7, October 1999 (1999-10-01), pages 1415 - 21, XP001064820 *
PALMA G ET AL: "Case-control study of interactions between genetic environmental factors in Parkinson's disease", LANCET, vol. 52, 19 December 1998 (1998-12-19), pages 1986 - 87, XP002196457 *
RAHBAR A ET AL: "Glutathionine S-transferase polymorphism in Parkinson's disease", JOURNAL OF NEURAL TRANSMISSION, vol. 107, no. 3, March 2000 (2000-03-01), pages 331 - 34, XP001064823 *
STROOMBERGEN C ET AL: "Determination of glutathione S-transferase mu and theta polymorphisms in neurological disease", HUMAN AND EXPERIMENTAL TOXICOLOGY, vol. 18, no. 3, March 1999 (1999-03-01), pages 141 - 45, XP001064817 *
TAN E ET AL: "Variability and validity of polymorphism association studies in Parkinson?s disease", NEUROLOGY, vol. 55, no. 4, August 2000 (2000-08-01), pages 533 - 38, XP001064819 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7309497B2 (en) 2000-08-24 2007-12-18 Schwarz Pharma Ag Injectable pharmaceutical composition for systematic administration of pharmacologically active ingredients

Also Published As

Publication number Publication date
FR2828212B1 (fr) 2003-10-31
AU2002341044A1 (en) 2003-02-17
FR2828212A1 (fr) 2003-02-07
WO2003012137A2 (fr) 2003-02-13

Similar Documents

Publication Publication Date Title
WO2004088309A3 (fr) Methodes de diagnostic de troubles du tractus urinaire et de la prostate
WO2005051178A3 (fr) Marqueur pour la neuromyelite optique
WO1999052942A3 (fr) Sequence genomique de la proteine activant 5-lipogenase (flap), marqueurs polymorphes correspondants et procede de detection de l'asthme
AU5212199A (en) Methods and kits for diagnosing and determination of the predisposition of diseases
AU2001263504A1 (en) System and method for determining affinity using objective and subjective data
AU2003245689A8 (en) Method for testing the integrity of dpf's
WO2004001421A3 (fr) Procede de diagnostic et diagnostic differentiel des maladies neurologiques
EP0969385A3 (fr) Méthode d'évaluation d'un algorithme héréditaire
AU2002364277A1 (en) Method for the assessment and prognosis of sarcoidosis
WO2003073211A3 (fr) Procede de realisation de tests de performances en continu
WO2004089184A3 (fr) Nouvelles utilisations de la lp-pla2 en combinaison pour evaluer le risque coronaire
WO2003012137A3 (fr) Methodes de detection de la maladie de parkinson
WO2001087142A3 (fr) Procede destine a determiner les variations de l'etat d'attention et l'etat d'attention general
WO2004107958A3 (fr) Marqueurs de sterol utilises en tant qu'outils de diagnostic dans la prevention des maladies atherosclereuses et en tant qu'outils d'aide a la selection d'agents a utiliser dans la prevention et le traitement de maladies atherosclereuses
AU4135001A (en) Method and apparatus for performing prefetching at the critical section level
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
WO2004039321A8 (fr) Therapie associee agoniste nicotinique/agoniste d1 pour le traitement de la maladie d'alzheimer
WO2003052121A3 (fr) Procede de reduction de l'angiogenese
WO2001007644A3 (fr) Genotypage du gene de la paraoxonase i pour le pronostic, le diagnostic et le traitement d"une maladie
AU2003260808A1 (en) Method for determining the risk of developing a skeletal condition
WO2004035597A3 (fr) Procede permettant d'evaluer le risque d'echec de la reproduction par mesure de la longueur d'un telomere
WO2002065137A3 (fr) Diagnostic
WO2004016744A3 (fr) Traitement de maladies du foie
WO2002046475A3 (fr) Procede de detection et de traitement de pathologies associees au syndrome de la sclerose tubereuse
WO2003100090A3 (fr) Polymorphismes de proteine c utiles en tant qu'indicateurs de resultat pour le patient

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载